Year: 2024

Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025 Ongoing clinical studies evaluating navacaprant in bipolar depression and NMRA-511 in Alzheimer’s disease agitation with data expected in second half of 2025 Clinical study for next M4 PAM program expected to commence clinical in the first half of 2025 Strong financial position with $341.3 million in cash, cash equivalents and marketable securities now expected to support operations into mid-2026 Conference call today at 8:00am ET WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced...

– EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU– Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at ESMO-IO– Completed enrollment of EOS-984 Phase 1 monotherapy dose escalation and initiated dosing of EOS-984 + pembrolizumab combination– Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 12, 2024 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results...

– Secures Favorable Initial Ruling in ITC Case Against Voltage, LLC – – Quarterly Revenue of $102.2 million – – Gross Profit Percentage of 24.8% and Adjusted Gross Profit Percentage of 37.9% – – Net Loss of $0.3 million – – Adjusted EBITDA of $24.5 million – – Raises Midpoint of Full-Year Revenue Outlook – PORTLAND, Tenn., Nov. 12, 2024 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a leading provider of electrical balance of system (“EBOS”) solutions for the energy transition market, today announced results for its third quarter ended September 30, 2024. “I’m pleased with the robust engagement we experienced in the third quarter. Customers remain cautious yet constructive as we head into the end of 2024 and look into 2025. Quoting volume across our customer base is at record levels,...

SLINGERLANDS, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, today announced further progress on its strategic and operational initiatives and path to profitability in the third quarter of 2024. These developments underscore the Company’s commitment to advancing the hydrogen economy and solidifying its market and financial position in the industry. Financial HighlightsQ3 Financial Performance: Plug reported revenue of $173.7 million in Q3 2024, representing an inflection in electrolyzer deployments, continued expansion of its internally produced hydrogen network, and increased leverage on its manufacturing footprint.Operating Cash Flows: Improved 31% Quarter-Over-Quarter (QoQ) reflecting improvement in margins,...

Interim Management Statement covering Q1 2024/25 The Board of Directors of Rovsing A/S has today reviewed and approved the Interim Management Statement for the first quarter (1 July 2024– 30 September 2024) of the financial year 2024/25. Q1 highlightsFor the Q1 of the financial year 2024/25, revenue, EBITDA and EBIT are in line with expectations.In Q1, the revenue amounted to DKK 9.5 million (Q1 2023/24: DKK 8.1 million) or an increase of 17.3% (DKK 1.4 million).EBITDA in Q1 amounted to DKK 0.8 million (Q1 2023/24: DKK 0.6 million) or an increase of DKK 0.2 million.EBIT in Q1 amounted to DKK 0.3 million (Q1 2023/24: DKK 0.1 million) or an increase of DKK 0.2 million.Order intake in Q1 amounted to DKK 11.2 million and the Company maintains a healthy and diverse order backlog of DKK 40.5 million at end of September 2024, ranging...

BERKELEY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) — Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced its financial results for the third quarter ended September 30, 2024 and business updates, including updates to its technology roadmap. Third Quarter 2024 Financial HighlightsTotal revenues for the three months ended September 30, 2024 were $2.4 million Total operating expenses for the three months ended September 30, 2024 were $18.6 million Operating loss for the three months ended September 30, 2024 was $17.3 million Net loss for the three months ended September 30, 2024 was $14.8 million As of September 30, 2024 cash, cash equivalents and available-for-sale securities totaled $92.6 millionTechnology Updates Roadmap updateThe Company plans...

– Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highlight further reductions in tumor size, increase in ORR, sustained improvement in desmoid tumor symptoms, and consistent safety profile – – Granted FDA Priority Review on NDA and received validation of EU Marketing Authorization Application for mirdametinib for the treatment of adults and children with NF1-PN – – $498 million in cash, cash equivalents and marketable securities as of September 30, 2024; expected to fund the Company through profitability, which is anticipated in the first half of 2026 – – Conference call and webcast scheduled for 8:30 a.m. ET today – STAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) — SpringWorks Therapeutics,...

WILLIAMSBURG, Va., Nov. 12, 2024 (GLOBE NEWSWIRE) — Sotherly Hotels Inc. (NASDAQ: SOHO), (“Sotherly” or the “Company”), a self-managed and self-administered lodging real estate investment trust (a “REIT”), today reported its consolidated results for the third quarter ended September 30, 2024. The Company’s results include the following*:  Three Months Ended     Nine Months Ended    September 30, 2024     September 30, 2023     September 30, 2024     September 30, 2023    ($ in thousands except per share data)     ($ in thousands except per share data)  Total revenue $ 40,700     $ 39,181     $ 137,943     $ 131,690  Net loss attributable to common stockholders   (5,604 )     (3,904 )     (3,641 )     (1,353 )                       EBITDA   6,424       6,539       31,501       30,589  Hotel EBITDA   8,087       7,567       36,145       34,488                         FFO...